Jaya, Halim Priyahau
Unknown Affiliation

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

Pola Penggunaan Levofloxacin pada Pasien HIV dan AIDS di UPIPI RSUD DR. Soetomo Surabaya Pambudi, Rien Esti; Triyono, Erwin Astha; Surdijati, Siti; Jaya, Halim Priyahau
Jurnal Farmasi Sains dan Terapan Vol 5, No 2 (2018)
Publisher : Jurnal Farmasi Sains dan Terapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (234.807 KB) | DOI: 10.33508/jfst.v5i2.2142

Abstract

HIV is a retrovirus (RNA) that attacks the human immune system. AIDS is a retrovirus disease characterized by immunosuppression which causes opportunistic infectious diseases. Opportunistic infections appear with new forms of infection by other microorganisms or reactivation of latent infections under normal conditions that can be controlled by the immune system so as not to cause manifestations. Opportunistic infections show effects on immunity associated with CD4 cell counts. The therapy used to reduce opportunistic infections is levofloxacin. Based on research, levofloxacin for HIV AIDS patients is often used to reduce opportunistic infections including bacterial pneumonia, tuberculosis and sepsis. This study aims to provide data that includes levofloxacin therapeutic doses, frequency use, old route drugs, prevalence and interaction of qualitative analysis related to medical records in HIV & AIDS patients at UPIPI DR. Soetomo Regional General Hospital Surabaya. The research method used is a retrospective observational study on medical records of patients with HIV & AIDS. Sampling was done by consecutive sampling in the period January 1, 2015 to June 30, 2015. The results obtained from the most relevant types of research, dose, frequency and route were levofloxacin for the treatment of opportunistic infections, especially bacterial pneumonia, tuberculosis, and sepsis. in oral doses and injections at a dose of 500 mg and a frequency of 750 mg 1x1. The use of levofloxacin given to HIV & AIDS patients at UPIPI DR. Surabaya Soetomo Regional General Hospital, related to dosage, route, frequency, interval, and duration of administration is in accordance with existing guidelines.
Pola Penggunaan Ranitidine pada Pasien HIV & AIDS di UPIPI RSUD DR. Soetomo Surabaya Nurohmawati, Weni; Triyono, Erwin Astha; Surdijati, Siti; Jaya, Halim Priyahau
Jurnal Farmasi Sains dan Terapan Vol 4, No 2 (2017)
Publisher : Jurnal Farmasi Sains dan Terapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (399.527 KB) | DOI: 10.33508/jfst.v4i2.2182

Abstract

HIV is a retrovirus that attacks CD4 lymphocyte cells. AIDS is a retrovirus disease caused by infection with retrovirus HIV-1 or HIV-2 which causes opportunistic diseases, secondary neoplasms and neurological abnormalities. In patients with HIV & AIDS often experience gastrointestinal disorders such as nausea and vomiting caused by side effects of the use of antiretroviral or due to other factors. Ranitidine is an H2 inhibitory receptor that will selectively and reversibly reduce excess gastric acid secretion. In this study ranitidine was used as a stress ulcer prophylaxis in hospitalized patients. This study aims to display ranitidine therapy data including type, dose, route of drug administration, prevalence, duration of use and qualitative analysis of interactions associated with medical record data at UPIPI RSUD Dr. Soetomo Surabaya. The research method used was observational prospectively on patient medical record with HIV & AIDS. Sampling was carried out by consecutive sampling period from November 1, 2016 to December 31, 2016. The results of this study give information that ranitidine was most widely used for stress ulcer prophylaxis therapy in hospitalized patients in UPIPI RSUD Dr. Soetomo Surabaya in a dose of 50mg / 2ml with a frequency of 2x1 while for oral ranitidine with a dose of 150mg / tablet with a frequency of 2x1. The use of ranitidine on HIV & AIDS patients in UPIPI RSUD Dr Soetomo Surabaya, related to dosage, route, frequency, interval, and duration of administration is in accordance with the existing guidelines.
Pola Penggunaan Levofloxacin pada Pasien HIV dan AIDS di UPIPI RSUD DR. Soetomo Surabaya Pambudi, Rien Esti; Triyono, Erwin Astha; Surdijati, Siti; Jaya, Halim Priyahau
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol. 5 No. 2 (2018)
Publisher : Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v5i2.2142

Abstract

HIV is a retrovirus (RNA) that attacks the human immune system. AIDS is a retrovirus disease characterized by immunosuppression which causes opportunistic infectious diseases. Opportunistic infections appear with new forms of infection by other microorganisms or reactivation of latent infections under normal conditions that can be controlled by the immune system so as not to cause manifestations. Opportunistic infections show effects on immunity associated with CD4 cell counts. The therapy used to reduce opportunistic infections is levofloxacin. Based on research, levofloxacin for HIV AIDS patients is often used to reduce opportunistic infections including bacterial pneumonia, tuberculosis and sepsis. This study aims to provide data that includes levofloxacin therapeutic doses, frequency use, old route drugs, prevalence and interaction of qualitative analysis related to medical records in HIV & AIDS patients at UPIPI DR. Soetomo Regional General Hospital Surabaya. The research method used is a retrospective observational study on medical records of patients with HIV & AIDS. Sampling was done by consecutive sampling in the period January 1, 2015 to June 30, 2015. The results obtained from the most relevant types of research, dose, frequency and route were levofloxacin for the treatment of opportunistic infections, especially bacterial pneumonia, tuberculosis, and sepsis. in oral doses and injections at a dose of 500 mg and a frequency of 750 mg 1x1. The use of levofloxacin given to HIV & AIDS patients at UPIPI DR. Surabaya Soetomo Regional General Hospital, related to dosage, route, frequency, interval, and duration of administration is in accordance with existing guidelines.
Pola Penggunaan Ranitidine pada Pasien HIV & AIDS di UPIPI RSUD DR. Soetomo Surabaya Nurohmawati, Weni; Triyono, Erwin Astha; Surdijati, Siti; Jaya, Halim Priyahau
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol. 4 No. 2 (2017)
Publisher : Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v4i2.2182

Abstract

HIV is a retrovirus that attacks CD4 lymphocyte cells. AIDS is a retrovirus disease caused by infection with retrovirus HIV-1 or HIV-2 which causes opportunistic diseases, secondary neoplasms and neurological abnormalities. In patients with HIV & AIDS often experience gastrointestinal disorders such as nausea and vomiting caused by side effects of the use of antiretroviral or due to other factors. Ranitidine is an H2 inhibitory receptor that will selectively and reversibly reduce excess gastric acid secretion. In this study ranitidine was used as a stress ulcer prophylaxis in hospitalized patients. This study aims to display ranitidine therapy data including type, dose, route of drug administration, prevalence, duration of use and qualitative analysis of interactions associated with medical record data at UPIPI RSUD Dr. Soetomo Surabaya. The research method used was observational prospectively on patient medical record with HIV & AIDS. Sampling was carried out by consecutive sampling period from November 1, 2016 to December 31, 2016. The results of this study give information that ranitidine was most widely used for stress ulcer prophylaxis therapy in hospitalized patients in UPIPI RSUD Dr. Soetomo Surabaya in a dose of 50mg / 2ml with a frequency of 2x1 while for oral ranitidine with a dose of 150mg / tablet with a frequency of 2x1. The use of ranitidine on HIV & AIDS patients in UPIPI RSUD Dr Soetomo Surabaya, related to dosage, route, frequency, interval, and duration of administration is in accordance with the existing guidelines.
The Chemotherapy Use and Adverse Effects of Patients with Lung Cancer at Regional General Hospital in Surabaya, Indonesia Yulia, Rika; Kirtishanti, Aguslina; Wijono, Heru; Setiawan, Eko; Presley, Bobby; Go, Tjie Kok; Mayani, Ni Putu Irma; Febriani, Anna; Jaya, Halim Priyahau; Herawati, Fauna
Pharmaceutical Sciences and Research
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

In Indonesia, lung cancer is the leading cause of death related to cancer, according to Global Cancer Observatory. Chemotherapy is the most common treatment since it works systemically and can prevent cancer cells from spreading to other organs. Cytotoxicity of chemotherapy can also put patients at high risk of experiencing adverse effects. This study aimed to evaluate the congruity of chemotherapy use with treatment recommendations and the profile of adverse effects, not only acute but also delayed adverse drug reactions. This prospective observational study involved 41 adult patients with lung cancer who received chemotherapy. Data is collected through patients’ medical records, brief patient interviews, and analyzed descriptively. The majority of the patients received first-line chemotherapy (87.80%). Pemetrexed-cisplatin (39.02%) and pemetrexed-carboplatin (19.51%) are the most common first-line therapy, followed by docetaxel (12,20%) as the second-line chemotherapy commonly used by patients. The chemotherapy regimens used in patients were 100% appropriate based on treatment guidelines. 61.11% and 60% of patients experience adverse effects with the first and second line of chemotherapy, respectively. Anemia (63,89%) was the most common delayed adverse effect in the first-line chemotherapy and hair loss (60%) was the most common one in the second-line chemotherapy. The platinum-based chemotherapy is a standard treatment for lung cancer, but its tolerability limits its uses. These findings showed chemotherapy-related adverse effects that need to be considered in choosing the best choice of therapy to optimize the treatment. Therefore, prophylaxis therapy to manage chemotherapy-related adverse effects may be considered in patients with chemotherapy.